Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
10.22358/jafs/65719/2014 38
Key benefits Why people compare it 1 14.9% mean body weight reduction demonstrated in STEP 1 trial (N=1,961) 2 20% reduction in major adverse cardiovascular events in SELECT trial (N=17,604) 3 Significant reduction in appetite and food cravings via hypothalamic POMC/CART activation 4 Improved glycemic control with glucose-dependent insulin secretion potentiation 5 Once-weekly dosing enabled by 165-hour plasma half-life and albumin binding 6 86.4% of STEP 1 participants achieved at least 5% body weight loss 7 Demonstrated NAFLD/NASH improvement with reduction in liver fat content 8 Well-characterized safety profile from over 30,000 participants across STEP and SELECT programs Deep research Semaglutide (chemical name: N-epsilon26-[2-(2-[2-(2-[2-(2-((S)-2-carboxy-3-((1S,2R)-3-carboxy-1-(carboxymethyl-carbamoyl)-propylcarbamoyl)-propionylamino)-ethoxy)-ethoxy)-acetylamino]-ethoxy)-ethoxy)-acetyl]-[Aib8,Arg34]-GLP-1-(7-37)-peptide) is a 39-amino-acid peptide with a molecular weight of 4,113.58 Da
Its still in clinical trials, which means it isnt yet available as an approved treatment
Peptide therapy uses synthetic versions of these natural messengers to trigger specific responses in your body
Your providers records should clearly reflect your diagnosis Type 2 diabetes, cardiovascular disease, sleep apnea, or obesity using the correct ICD-10 codes
US$ 22.13
US$ 29.23
US$ 20.50
US$ 20.58
US$ 21.25
US$ 28.10
US$ 23.48
US$ 25.99
US$ 29.82
US$ 26.96
US$ 29.49
US$ 25.15
